Depomed diabetes drug gets another generic threat
Reuters | 05:32 PM,Jun 21,2011REUTERS - Depomed Inc filed a patent suit against Sun Pharmaceutical Industries Ltd in response to the Indian company's filing of a marketing application with U.S. health regulators for a copycat version of Depomed's diabetes drug Glumetza. In May, the specialty pharmaceutical company won a lawsuit against India's Lupin Ltd, which had also filed a marketing application with the U.S. Food and Drug Administration for generic versions of Glumetza. Depomed said it would continue to vigorously enforce its intellectual property rights to Glumetza tablets. Depomed shares closed at $7.78 on Monday on Nasdaq. (Reporting by Kavyanjali Kaushik in Bangalore; Editing by Gopakumar Warrier)
This is an automated news feed. The contents have not been selected or edited by IBNLive.
displayed with permission. Use of the CNN name and/or logo on or as part of CNN-IBN does not derogate from the intellectual property rights of Cable News Network in respect of them.
Disclaimer: Network18 Media & Investments Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at